Low Glycemic Index Diet Helpful in Men With Type 2 Diabetes
August 2, 2004 — A low glycemic index (LGI) diet improves glycemic control, some lipid profiles, and fibrinolysis in men with type 2 diabetes, according to the results of a randomized trial published in the August issue of Diabetes Care

Twenty Percent of Patients With Asymptomatic Diabetes Have...
July 30, 2004 — Twenty percent of patients with asymptomatic diabetes have silent myocardial ischemia, according to the results of the Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects (DIAD) study published in the August issue of Diabetes Care. These findings support the American Diabetes Association (ADA) guidelines recommending routine screening.

American Diabetes Association 64th Annual Scientific Sessions

Splenda

The Struggle for Mastery in Insulin Action:
ype 2 diabetes arises from a combination of impaired insulin action and defective pancreatic β-cell function. Classically, the two abnormalities have been viewed as distinct yet mutually detrimental processes. The combination of impaired insulin-dependent glucose metabolism in skeletal muscle and impaired β-cell function causes an increase of hepatic glucose production, leading to a constellation of tissue abnormalities that has been referred to as the diabetes "ruling triumvirate." Targeted mutagenesis in mice has led to a critical reappraisal of the integrated physiology of insulin action

Dual Blockade of Renin-Angiotensin System Renoprotective...: "Aug. 1, 2003 � Dual blockade of the renin-angiotensin system (RAS) is renoprotective in type 2 diabetes, according to the results of a double-blind, randomized trial published in the August issue of Diabetes Care. Adding an angiotensin II receptor blocker (ARB) to treatment with maximal recommended doses of an angiotensin-converting enzyme (ACE) inhibitor provided superior short-term renoprotection independent of systemic blood pressure changes."

Adding Thiazolidinedione to Metformin Plus Insulin Improves...: "July 1, 2004 � Adding thiazolidinedione to metformin (MET) plus insulin (INS) improved glycemic control and reduced INS dose without increasing weight gain, according to the results of a randomized trial published in the July issue of Diabetes Care. The editorialist suggests that treating to target is all that matters, regardless of what combination of medications is used. Cost and lifestyle should be considered in choosing optimal triple therapy."

News - Metformin Shows Promise for Diabetes Prevention, but Further Studies Needed
Metformin may help prevent type 2 diabetes in individuals at high risk of developing the disease, but new studies must evaluate its long-term safety, efficacy, cost-effectiveness, according to Donald L. Sullivan, PhD, RPh, and Aleda M. Hess, Pharm D, both of Ohio Northern University, Ada, United States.

News - Rosiglitazone Could Have Antiinflammatory Effects: "Thiazolidinedione rosiglitazone, a selective agonist of peroxisome proliferator-activated receptor gamma has demonstrated antiinflammatory effects, according to a new American study.

Troglitazone, a thiazolidinedione agonist of peroxisome proliferator-activated receptor gamma (PPAR�) and a partial agonist of PPAR�, was previously shown to have a significant antiinflammatory activity in a trial of diabetic obese patients and nondiabetic obese subjects, writes P. Mohanty, MD, and colleagues, Division of Endocrinology, Diabetes and Metabolism, State University of New York, New York."

Webcast/CME - Evolution of Type 2 Diabetes: The Time for Insulin is Now
This multi-media webcast reviews the goals of type 2 diabetes management, the benefits of intensive therapy, guidelines for measurement of glycaemic control, and practical strategies for helping achieve and maintain glycaemic control via intensive therapy methodologies

Adding Thiazolidinedione to Metformin Plus Insulin Improves...
July 1, 2004 — Adding thiazolidinedione to metformin (MET) plus insulin (INS) improved glycemic control and reduced INS dose without increasing weight gain, according to the results of a randomized trial published in the July issue of Diabetes Care. The editorialist suggests that treating to target is all that matters, regardless of what combination of medications is used. Cost and lifestyle should be considered in choosing optimal triple therapy.

MayoClinic.com - Diabetes Center

Rosuvastatin Label Change in EU Indicates Risk of Myopathy

June 10, 2004 — The U.S. Food and Drug Administration (FDA) issued a public health advisory yesterday, notifying healthcare professionals of labeling changes for rosuvastatin (Crestor, made by AstraZeneca) in the 22 member states of the European Union (EU). These changes, which are already in effect in FDA-approved labeling in the U.S., reflect the increased risk of myopathy associated with high levels of rosuvastatin.

Glucagon-like Peptide 1: Part II
The central role of GLP-1 in glucose tolerance has raised questions about the possible involvement of this peptide in the pathogenesis of diabetes. In addition, the wide range of coordinated actions by which GLP-1 lowers blood glucose has launched a new wave of drug development centered on this peptide hormone.

Incretin Hormones in Diabetes and Metabolism
Introduction
The Incretin Effect
The Incretin Hormones: GIP and GLP-1
Incretin Physiology and Type 2 Diabetes Mellitus
Current Status of Drugs in Development
Concluding Remarks
References

The Glycemic Index: "What is the Glycemic Index?
The glycemic index is a ranking of carbohydrates based on their immediate effect on blood glucose (blood sugar) levels. It compares foods gram for gram of carbohydrate. Carbohydrates that breakdown quickly during digestion have the highest glycemic indexes. The blood glucose response is fast and high. Carbohydrates that breakdown slowly, releasing glucose gradually into the blood stream, have low glycemic indexes."

ACE Inhibitors Improve Survival in Type 2 Diabetes: "May 27, 2004 � Angiotensin-converting enzyme (ACE) inhibitors significantly reduce all-cause mortality in patients with type 2 diabetes who do not have a history of cardiovascular disease, according to the results of a cohort study published in the June issue of Diabetes Care.
'ACE inhibitor therapy is widely used in lower-risk patients with type 2 diabetes to reduce mortality, despite limited evidence to support this clinical strategy,' write Dean T. Eurich, BSP, MSC, from the Institute of Health Economics in Edmonton, Alberta, Canada, and colleagues."

ACE Inhibitors Improve Survival in Type 2 Diabetes

May 27, 2004 — Angiotensin-converting enzyme (ACE) inhibitors significantly reduce all-cause mortality in patients with type 2 diabetes who do not have a history of cardiovascular disease, according to the results of a cohort study published in the June issue of Diabetes Care.

Aspirin-Like Treatment May Be Safe, Effective for Type 2 Diabetes
May 3, 2004 (Boston) — Salsalate, an aspirin-like anti-inflammatory agent, has shown promise as a type 2 diabetes treatment in a small pilot study at the Joslin Clinic.

Robert J. Silver, MD, a fellow in endocrinology and diabetes at the Boston-based diabetes center, reported that 3.0 g taken orally for two weeks was enough to reduce blood fasting glucose by 9% in nine patients. Other benefits included reductions of 12% in triglyceride and 15% in free fatty acid levels.

More Coffee, Less Diabetes - Diabetes Mellitus, Type 2, Type 1, and Metabolic Disorders treatment and medications
More Coffee, Less Diabetes
Authors' Conclusion: "Coffee drinking has a graded inverse association with the risk of type 2 DM; however, the reasons for this risk reduction associated with coffee remain unclear." (J. Tuomilehto and coauthors, JAMA. 2004;291:1213)

Our Translation: More coffee, less type 2 diabetes. We really have no idea why this is so.